Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - truvada
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp6471e64aafea74720593633f2a0cd695
identifier: http://ema.europa.eu/identifier
/EU/1/04/305/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Truvada 200 mg/245 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-6471e64aafea74720593633f2a0cd695
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/04/305/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - truvada
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Truvada contains two active substances, emtricitabine and tenofovir disoproxil. Both of these active substances are antiretroviral medicines which are used to treat HIV infection. Emtricitabine is a nucleoside reverse transcriptase inhibitor and tenofovir is a nucleotide reverse transcriptase inhibitor. However, both are generally known as NRTIs and they work by interfering with the normal working of an enzyme (reverse transcriptase) that is essential for the virus to reproduce itself.
Truvada should always be used combined with other medicines to treat HIV infection.
Truvada can be administered in place of emtricitabine and tenofovir disoproxil used separately at the same doses.
This medicine is not a cure for HIV infection. While taking Truvada you may still develop infections or other illnesses associated with HIV infection.
Do not take Truvada to treat HIV or to reduce the risk of getting HIV if you are allergic to emtricitabine, tenofovir, tenofovir disoproxil, or any of the other ingredients of this medicine (listed in section 6).
If this applies to you, tell your doctor immediately.
Before taking Truvada to reduce the risk of getting HIV:
Truvada can only help reduce your risk of getting HIV before you are infected.
You must be HIV negative before you start to take Truvada to reduce the risk of getting HIV. You must get tested to make sure that you do not already have HIV infection. Do not take Truvada to reduce your risk unless you are confirmed to be HIV negative. People who do have HIV must take Truvada in combination with other drugs.
Many HIV tests can miss a recent infection. If you get a flu-like illness, it could mean you have recently been infected with HIV. These may be signs of HIV infection:
tiredness
fever
joint or muscle aches
headache
vomiting or diarrhoea
rash
night sweats
enlarged lymph nodes in the neck or groin
Tell your doctor about any flu-like illness either in the month before starting Truvada, or at any time while taking Truvada.
Warnings and precautions
While taking Truvada to reduce the risk of getting HIV:
Take Truvada every day to reduce your risk, not just when you think you have been at risk of HIV infection. Do not miss any doses of Truvada, or stop taking it. Missing doses may increase your risk of getting HIV infection.
Get tested for HIV regularly.
If you think you were infected with HIV, tell your doctor straight away. They may want to do more tests to make sure you are still HIV negative.
Just taking Truvada may not stop you getting HIV. * Always practice safer sex. Use condoms to reduce contact with semen, vaginal fluids, or blood. * Do not share personal items that can have blood or body fluids on them, such as toothbrushes and razor blades. * Do not share or re-use needles or other injection or drug equipment. * Get tested for other sexually transmitted infections such as syphilis and gonorrhoea.
These infections make it easier for HIV to infect you.
Ask your doctor if you have any more questions about how to prevent getting HIV or spreading HIV to other people.
While taking Truvada to treat HIV or to reduce the risk of getting HIV:
Truvada may affect your kidneys. Before and during treatment, your doctor may order blood tests to measure kidney function. Tell your doctor if you have had kidney disease, or if tests have shown kidney problems. Truvada should not be given to adolescents with existing kidney problems. If you have kidney problems, your doctor may advise you to stop taking Truvada or, if you already have HIV, to take Truvada less frequently. Truvada is not recommended if you have severe kidney disease or are on dialysis.
Talk to your doctor if you suffer from osteoporosis, have a history of bone fracture or if you have problems with your bones.
Bone problems (manifesting as persistent or worsening bone pain and sometimes resulting in fractures) may also occur due to damage to kidney tubule cells (see section 4, Possible side effects). Tell your doctor if you have bone pain or fractures.
Tenofovir disoproxil may also cause loss of bone mass. The most pronounced bone loss was seen in clinical studies when patients were treated for HIV with tenofovir disoproxil in combination with a boosted protease inhibitor.
Overall, the effects of tenofovir disoproxil on long term bone health and future fracture risk in adult and paediatric patients are uncertain.
Talk to your doctor if you have a history of liver disease, including hepatitis. Patients infected with HIV who also have liver disease (including chronic hepatitis B or C), who are treated with antiretrovirals, have a higher risk of severe and potentially fatal liver complications.
If you have hepatitis B or C, your doctor will carefully consider the best treatment regimen for you.
Know your hepatitis B virus (HBV) infection status before starting Truvada. If you have HBV, there is a serious risk of liver problems when you stop taking Truvada, whether or not you also have HIV. It is important not to stop taking Truvada without talking to your doctor: see section 3, Do not stop taking Truvada.
Talk to your doctor if you are over 65. Truvada has not been studied in patients over 65 years of age.
Talk to your doctor if you are intolerant to lactose (see Truvada contains lactose later in this section).
Children and adolescents
Truvada is not for use in children under 12 years of age.
Other medicines and Truvada
Do not take Truvada if you are already taking other medicines that contain the components of Truvada (emtricitabine and tenofovir disoproxil) or any other antiviral medicines that contain tenofovir alafenamide, lamivudine or adefovir dipivoxil.
Taking Truvada with other medicines that can damage your kidneys: it is especially important to tell your doctor if you are taking any of these medicines, including
If you are taking another antiviral medicine called a protease inhibitor to treat HIV, your doctor may order blood tests to closely monitor your kidney function.
It is also important to tell your doctor if you are taking ledipasvir/sofosbuvir, sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir to treat hepatitis C infection.
Taking Truvada with other medicines containing didanosine (for treatment of HIV infection): Taking Truvada with other antiviral medicines that contain didanosine can raise the levels of didanosine in your blood and may reduce CD4 cell counts. Rarely, inflammation of the pancreas and lactic acidosis (excess lactic acid in the blood), which sometimes causes death, have been reported when medicines containing tenofovir disoproxil and didanosine were taken together. Your doctor will carefully consider whether to treat you with combinations of tenofovir and didanosine.
Tell your doctor if you are taking any of these medicines. Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Truvada with food and drink
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
If you have taken Truvada during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.
Do not breast-feed during treatment with Truvada. This is because the active substances in this medicine pass into human breast milk.
Breast-feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby in breast milk.
If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as soon as possible.
Driving and using machines
Truvada can cause dizziness. If you feel dizzy while taking Truvada, do not drive and do not use any tools or machines.
Truvada contains lactose
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Truvada contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .
The recommended dose of Truvada to treat HIV is:
The recommended dose of Truvada to reduce the risk of getting HIV is:
If you have difficulty swallowing, you can use the tip of a spoon to crush the tablet. Then mix the powder with about 100 mL (half a glass) of water, orange juice or grape juice, and drink immediately.
Always take the dose recommended by your doctor. This is to make sure that your medicine is fully effective, and to reduce the risk of developing resistance to the treatment. Do not change the dose unless your doctor tells you to.
If you are being treated for HIV infection your doctor will prescribe Truvada with other antiretroviral medicines. Please refer to the patient information leaflets of the other antiretrovirals for guidance on how to take those medicines.
If you are taking Truvada to reduce the risk of getting HIV, take Truvada every day, not just when you think you have been at risk of HIV infection.
Ask your doctor if you have any questions about how to prevent getting HIV or prevent spreading HIV to other people.
If you take more Truvada than you should
If you accidentally take more than the recommended dose of Truvada, contact your doctor or nearest emergency department for advice. Keep the tablet bottle with you so that you can easily describe what you have taken.
If you miss a dose
It is important not to miss a dose of Truvada.
If you vomit less than 1 hour after taking Truvada, take another tablet. You do not need to take another tablet if you were sick more than 1 hour after taking Truvada.
Do not stop taking Truvada
If you take Truvada for treatment of HIV infection, stopping tablets may reduce the effectiveness of the anti-HIV therapy recommended by your doctor.
If you are taking Truvada to reduce the risk of getting HIV, do not stop taking Truvada or miss any doses. Stopping use of Truvada, or missing doses, may increase your risk of getting HIV infection.
Do not stop taking Truvada without contacting your doctor.
Tell your doctor immediately about new or unusual symptoms after you stop treatment, particularly symptoms you associate with hepatitis B infection
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Possible serious side effects:
If you think you may have lactic acidosis, get medical help immediately.
Any signs of inflammation or infection. In some patients with advanced HIV infection (AIDS) and a history of opportunistic infections (infections that occur in people with a weak immune system), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. It is thought that these symptoms are due to an improvement in the body s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
Autoimmune disorders, when the immune system attacks healthy body tissue, may also occur after you start taking medicines to treat HIV infection. Autoimmune disorders may occur many months after the start of treatment. Look out for any symptoms of infection or other symptoms such as:
muscle weakness
weakness beginning in the hands and feet and moving up towards the trunk of the body
palpitations, tremor or hyperactivity
If you notice these or any symptoms of inflammation or infection, get medical help immediately.
Possible side effects:
Very common side effects
(may affect more than 1 in 10 people)
Tests may also show:
Common side effects (may affect up to 1 in 10 people)
Tests may also show:
Uncommon side effects (may affect up to 1 in 100 people)
Tests may also show:
Rare side effects (may affect up to 1 in 1,000 people)
Damage to kidney tubule cells may be associated with breakdown of muscle, softening of the bones (with bone pain and sometimes resulting in fractures), muscle pain, muscle weakness and decreases in potassium or phosphate in the blood.
If you notice any of the side effects listed above or if any of the side effects get serious, talk to your doctor or pharmacist.
The frequency of the following side effects is not known.
If you notice any of these symptoms tell your doctor.
During treatment for HIV there may be an increase in weight and in levels of blood lipids and glucose.
This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.
Other effects in children
If you notice any of these symptoms tell your doctor.
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle and carton after {EXP}.
The expiry date refers to the last day of that month.
Store in the original package in order to protect from moisture. Keep the bottle tightly closed.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Truvada contains
The active substances are emtricitabine and tenofovir disoproxil. Each Truvada film-coated tablet contains 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg of tenofovir disoproxil fumarate or 136 mg of tenofovir).
The other ingredients are croscarmellose sodium (E468), glycerol triacetate (E1518), hypromellose (E464), indigo carmine aluminium lake (E132), lactose monohydrate, magnesium stearate (E572), microcrystalline cellulose (E460), pregelatinised starch (gluten free) and titanium dioxide (E171).
What Truvada looks like and contents of the pack
Truvada film-coated tablets are blue, capsule-shaped tablets, engraved on one side with the word GILEAD and on the other side with the number 701 . Truvada comes in bottles of 30 tablets.
Each bottle contains a silica gel desiccant that must be kept in the bottle to help protect your tablets.
The silica gel desiccant is contained in a separate sachet or canister and should not be swallowed.
The following pack sizes are available: outer cartons containing 1 bottle of 30 film-coated tablets and 60 (2 bottles of 30) and 90 (3 bottles of 30) film-coated tablets. Not all pack sizes may be marketed.
Marketing Authorisation Holder: Gilead Sciences Ireland UC Carrigtohill County Cork, T45 DPIreland
Manufacturer: Gilead Sciences Ireland UC IDA Business & Technology Park Carrigtohill County Cork Ireland
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Gilead Sciences Belgium SRL-BV T l/Tel: + 32 (0) 24 01 35 Lietuva Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1
Gilead Sciences Ireland UC .: + 353 (0) 1 686 1Luxembourg/Luxemburg Gilead Sciences Belgium SRL-BV T l/Tel: + 32 (0) 24 01 35 esk republika Gilead Sciences s.r.o. Tel: + 420 910 871 Magyarorsz g Gilead Sciences Ireland UC Tel.: + 353 (0) 1 686 1Danmark Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1Malta Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1Deutschland Gilead Sciences GmbH Tel: + 49 (0) 89 899890-0
Nederland Gilead Sciences Netherlands B.V. Tel: + 31 (0) 20 718 36 Eesti Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1Norge Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1
Gilead Sciences . . : + 30 210 8930 sterreich Gilead Sciences GesmbH Tel: + 43 1 260 Espa a Gilead Sciences, S.L. Tel: + 34 91 378 98 Polska Gilead Sciences Poland Sp. z o.o. Tel.: + 48 22 262 8France Gilead Sciences T l: + 33 (0) 1 46 09 41 Portugal Gilead Sciences, Lda. Tel: + 351 21 7928Hrvatska Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1Rom nia Gilead Sciences (GSR) S.R.L Tel: + 40 31 631 18 Ireland Gilead Sciences Ireland UC Tel: + 353 (0) 214 825 Slovenija Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1 sland Gilead Sciences Sweden AB S mi: + 46 (0) 8 5057 1Slovensk republika Gilead Sciences Slovakia s.r.o. Tel: + 421 232 121 Italia Gilead Sciences S.r.l. Tel: + 39 02 439Suomi/Finland Gilead Sciences Sweden AB Puh/Tel: + 46 (0) 8 5057 1
Gilead Sciences . . : + 30 210 8930 Sverige Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1Latvija Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1United Kingdom (Northern Ireland) Gilead Sciences Ireland UC Tel: + 44 (0) 8000 113 This leaflet was last revised in.
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-6471e64aafea74720593633f2a0cd695
Resource Composition:
Generated Narrative: Composition composition-en-6471e64aafea74720593633f2a0cd695
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/04/305/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - truvada
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp6471e64aafea74720593633f2a0cd695
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp6471e64aafea74720593633f2a0cd695
identifier:
http://ema.europa.eu/identifier
/EU/1/04/305/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Truvada 200 mg/245 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en